VRDN
Chart
Ratings & dials
1m · 5m · 15m · 1h · 4h · 1DAnalyst & Morningstar ratings
Consensus · Targets · MorningstarThird-party ratings, not SURVYR.'s views.
Health check
See the tests
- ✗Positive net income
- ✗Positive operating cash flow
- ✗Return on assets improved
- ✓Cash flow above net income
- ✓Long-term debt / assets fell
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Key stats & company
What they do
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.10 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-2.75 vs trailing $-3.32. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 1.4 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $70.8M | $-342.6M | $-276.9M |
| 2024 | $302.0K | $-269.9M | $-232.8M |
| 2023 | $314.0K | $-237.7M | $-185.1M |
| 2022 | $1.8M | $-129.9M | $-94.6M |
| 2021 | $3.0M | $-79.4M | $-54.9M |
| 2020 | $1.1M | $-110.7M | $-29.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +241.9%.
For information only · Important disclosures
Grades vs sector
No sector grades for VRDN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Held by 1 of 7 live models: SURVYR. Long Book.
Earnings & events
VRDN earningsNext report in 7 daysIn line = within 1% of the estimate.
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $284.0K | +278.7% |
| 2026-03-31 | $141.0K | – |
| 2025-12-31 | $132.0K | – |
| 2025-09-30 | $70.6M | – |
| 2025-06-30 | $75.0K | – |
News & catalysts
More newsRating changes
Third-party analyst actions, not SURVYR.'s views. All rating changes
Insider trades
$245.0K
$103.2K
–
Stats refreshed 2026-10-23 23:24:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026